SILV
SILVERCREST METALS INC
$81.68
+3.27%
No data for this timeframe.
Vol
Inst. Holders1 funds
Inst. Value$367.4K
Inst. Activity0 buys / 14 sells
Prev Close $79.09
Recent Activity
Inst.
D. E. Shaw & — EXIT
0 shares ($0.00)
Inst.
DIMENSIONAL FUND ADVISORS LP — EXIT
0 shares ($0.00)
Analyst Ratings
1Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BARCLAYS PLC | $367.4K | — |
1 institutional holders with $367.4K total value (39,714 shares) as of 2025-Q3. Top holders: BARCLAYS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | 39,714 | $367.4K | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| D. E. Shaw & Co., Inc. | EXIT | 1,898,946 | 0 | -100.0% | $0.00 | 2025-Q1 |
| DIMENSIONAL FUND ADVISORS LP | EXIT | 1,934,721 | 0 | -100.0% | $0.00 | 2025-Q1 |
| TD ASSET MANAGEMENT INC | EXIT | 1,814,852 | 0 | -100.0% | $0.00 | 2025-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | EXIT | 1,421,604 | 0 | -100.0% | $0.00 | 2025-Q1 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | EXIT | 1,950,000 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MACKENZIE FINANCIAL CORP | EXIT | 1,671,128 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | EXIT | 3,437,219 | 0 | -100.0% | $0.00 | 2025-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | EXIT | 1,219,842 | 0 | -100.0% | $0.00 | 2025-Q1 |
| Grantham, Mayo, Van Otterloo & Co. LLC | EXIT | 2,389,564 | 0 | -100.0% | $0.00 | 2025-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | EXIT | 2,131,375 | 0 | -100.0% | $0.00 | 2025-Q1 |
| JUPITER ASSET MANAGEMENT LTD | EXIT | 4,193,102 | 0 | -100.0% | $0.00 | 2025-Q1 |
| Magnetar Financial LLC | EXIT | 3,623,996 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITIGROUP INC | EXIT | 1,370,109 | 0 | -100.0% | $0.00 | 2025-Q1 |
| ROYAL BANK OF CANADA | EXIT | 1,538,807 | 0 | -100.0% | $0.00 | 2025-Q1 |
| Magnetar Financial LLC | NEW | — | 3,623,996 | — | $33.0M | 2024-Q4 |
| Grantham, Mayo, Van Otterloo & Co. LLC | NEW | — | 2,389,564 | — | $21.7M | 2024-Q4 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 121,413 | 1,421,604 | +1070.9% | $12.9M | 2024-Q4 |
| CITIGROUP INC | DOUBLED | 6,166 | 1,370,109 | +22120.4% | $12.5M | 2024-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | NEW | — | 1,219,842 | — | $11.1M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 292,400 | 872,500 | +198.4% | $7.9M | 2024-Q4 |
| BANK OF MONTREAL /CAN/ | ADD | 645,270 | 869,537 | +34.8% | $7.9M | 2024-Q4 |
| NATIONAL BANK OF CANADA /FI/ | ADD | 401,021 | 608,221 | +51.7% | $5.5M | 2024-Q4 |
| UBS Group AG | DOUBLED | 66,093 | 347,540 | +425.8% | $3.2M | 2024-Q4 |
| GROUP ONE TRADING LLC | TRIM | 551,086 | 278,810 | -49.4% | $2.5M | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 626,395 | 173,181 | -72.4% | $1.6M | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 63% buy across 8 analysts — 1 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | 1 | 4 | 3 | 0 | 0 | 63% | |
| Mar 1, 2025 | 1 | 4 | 3 | 0 | 0 | 63% | |
| Feb 1, 2025 | 1 | 4 | 3 | 0 | 0 | 63% | |
| Jan 1, 2025 | 1 | 5 | 4 | 0 | 0 | 60% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.